Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Glioma 1

Interventions

trametinib 3dabrafenib 3binimetinib 2Trastuzumab 2Paclitaxel 2Nivolumab 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Docetaxel 2ulixertinib 1trastuzumab biosimilar HLX02 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1larotrectinib 1ipatasertib 1glutathione pegylated liposomal doxorubicin 1erdafitinib 1entinostat 1diazepinomicin 1defactinib 1copanlisib 1cobimetinib 1clevudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × cabiralizumab × Thoracic × Clear all
NCT02526017 2022-03-09

FPA008-003

Five Prime Therapeutics, Inc.

Phase 1 Completed
313 enrolled 30 charts
CNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioma, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡